ABEO · Abeona Therapeutics
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $2.55
Note written ·
Price against the kill line
5.1% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $2.55, on record since 11 November 2026. The shares are down 59.3% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $2.55, which would recover the 9 November 2026 post-report drop and show the shares leading the S&P 500. A fourth-quarter report with ZEVASKYN revenue recognized for every treated patient and above the third quarter's $13.5 million would also show it.
Research onlyNot in the portfolio.
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 9 November 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 13.5
- Gross margin (%)
- 57.7
- Operating margin (%)
- −96.4
- Free cash flow, four quarters ($M)
- −66.3
- Net cash, cash less debt ($M)
- 123
- Enterprise value to sales (×)
- 0.4
- Free-cash-flow yield (%)
- −48.0
All filed numbers
What Abeona Therapeutics reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 13.5 | — | 57.7 | −96.4 |
| first filed | 11.4 | +2745.0 | 63.3 | −120.0 |
| first filed | 8.7 | — | 69.1 | −264.1 |
| first filed | 5.4 | — | 80.7 | −422.7 |
| first filed | 0.0 | — | — | — |
| first filed | 0.4 | — | — | −5698.0 |
| Pre-tax income ($M) | −4.8 |
| Net income ($M) four quarters: −62.5 | −4.8 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +6.7 |
| Operating cash flow ($M) | −63.6 |
| Capital spending ($M) | 2.8 |
| Free cash flow ($M) | −66.3 |
| Cash and short-term investments ($M) | 135 |
| Debt ($M) long-term debt | 11.8 |
| Net cash, cash less debt ($M) | 123 |
| Deferred revenue ($M) | 0.7 |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | 15.7 |
| Inventory ($M) | 4.7 |
| Shareholders' equity ($M) | 126 |
| Market value ($M) | 138 |
| Enterprise value, market value plus net debt ($M) | 15.2 |
| Enterprise value to sales (×) | 0.4 |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 1.1 |
| Free-cash-flow yield (%) | −48.0 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 30.1% of shares outstanding sold short, 12.7 days of average trading to cover, +2.0% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $297K |
| 12 monthsfrom | $0 | $3.5M |
The thesis
Abeona Therapeutics' ZEVASKYN skin-gene-therapy launch is still growing, but the third-quarter report missed estimates and the company paired it with a discounted share sale, so the shares are more likely to lag the S&P 500 over the next three months. The fourth-quarter report, which shows whether every treated patient converts into recognized revenue, settles it.
Abeona reported net ZEVASKYN revenue of $13.5 million for the quarter ended 30 September 2026 on 9 November 2026, up 18% from $11.4 million in the second quarter. Company news put revenue at $13.491 million against an analyst estimate of $16.484 million. The shares closed at $4.17 on 6 November 2026 and $2.54 on 9 November 2026, the first session after the report and financing.
The same day Abeona agreed to buy ABO-801, a Phase 3-ready oral tablet for eosinophilic esophagitis (EoE, an allergic inflammation of the food pipe), from Ellodi Pharmaceuticals, and sold $30 million of stock in a private placement. The placement was priced at $3.75 a share, per a Panabee summary of the company's release. The shares closed at $2.30 on 11 November 2026, their lowest close in 52 weeks.
Bullish and bearish views on Abeona Therapeutics Inc.
The bull case on Abeona Therapeutics Inc. (ABEO), in brief: product revenue keeps rising. The bear case: revenue missed expectations.
Bull case
- Product revenue keeps rising. Net ZEVASKYN revenue was $13.5 million in the third quarter, up 18% from $11.4 million in the second quarter, per Abeona's 8-K dated 9 November 2026. The second quarter had risen 31% from the first.
- Treatments are accelerating. Abeona has completed 15 ZEVASKYN treatments since launch, six of them in the third quarter, versus five in the second, per the 9 November 2026 release. Four of the eight qualified treatment centers have completed treatments.
- Reimbursement support took effect. New Technology Add-On Payment status for ZEVASKYN became effective on 1 October 2026, per the company's third-quarter release.
- Cash is larger after the placement. Cash, cash equivalents and short-term investments were $134.9 million at 30 September 2026, and the release says the $30 million of gross placement proceeds came in after quarter end. Perceptive Advisors, TPG, Marshall Wace, Nantahala Capital and Monashee were named as buyers in the Panabee summary.
- The new asset adds a second program. ABO-801 cost no upfront cash. Abeona issued $20 million of common stock and owes $30 million on FDA approval, up to $30 million in sales milestones and low-to-mid-teen percentage royalties, per the company's 8-K.
- An analyst still rates the shares a buy. HC Wainwright maintained a Buy rating on 12 November 2026 and lowered its price target to $18, per company news.
Bear case
- Revenue missed expectations. Revenue of $13.491 million fell short of the $16.484 million estimate, per company news on 9 November 2026. Growth slowed from 31% in the second quarter to 18% in the third.
- A batch failure again held back revenue. Abeona did not recognize revenue for one third-quarter treatment because its batch failed the identity assay release criterion, per the 9 November 2026 release. In the second quarter, revenue was recognized for four of five treatments. Two quarters are too few to measure a failure rate.
- The financing priced far above the market. The placement at $3.75 a share compares with closes of $2.54 on 9 November 2026 and $2.30 on 11 November 2026. The $20 million of stock to Ellodi adds further shares.
- Spending is rising on a small revenue base. Selling, general and administrative expenses were $17.1 million in the third quarter against $15.8 million in the second, and cost of sales rose to $5.7 million from $4.2 million, per the release. Abeona gave no cash runway estimate.
- Executives sold stock before the drop. SEC Form 4 filings show open-market sales at $5.16 on 29 September 2026 by Chief Executive Officer Vishwas Seshadri (19,608 shares), Chief Financial Officer Joseph Vazzano (9,191), Chief Legal Officer Brendan O'Malley (6,727) and Chief Commercial Officer Madhav Vasanthavada (4,902). Director Mark Alvino sold 15,000 shares at $5.86 on 1 September 2026.
Price setup
The shares closed at $2.30 on 11 November 2026, which is the 52-week closing low and 69.9% below the 52-week intraday high of $7.65 set on 11 August 2026. The three-month change is −63.8%.
The 50-day moving average is $4.84 and the 200-day moving average is $5.42, both as of 11 November 2026. The shares sit far below both, and the 50-day average now includes weeks of closes above $4.
The gap between sessions marks the break. The close was $4.17 on 6 November 2026, then $2.54 on 9 November 2026, $2.46 on 10 November 2026 and $2.30 on 11 November 2026. The shares have not rebounded since the report and have fallen below the $3.75 placement price.
The market has priced in a revenue miss, a dilutive financing and a new development program that needs a Phase 3 trial, with the closes above recording each step.
Catalysts ahead
- ~18 November 2026 (est.): Management presentation at the Jefferies Global Healthcare Conference, reported by BiopharmaWatch from Abeona's 10 November 2026 announcement. Management may address the batch failure, cash runway and plans for ABO-801 after the share price fell sharply.
What would change the view
A daily close above $2.55, which would recover the 9 November 2026 post-report drop and show the shares leading the S&P 500. A fourth-quarter report with ZEVASKYN revenue recognized for every treated patient and above the third quarter's $13.5 million would also show it.
What it trades with
Abeona trades with small-cap gene-therapy and rare-disease developers, so biotech funding conditions and interest rates move it alongside its peers. Its own drivers are ZEVASKYN treatment throughput, batch release yield and the cash cost of adding ABO-801. Large-cap index moves explain little of its price.
The evidence, claim by claim (8)
- Net ZEVASKYN revenue was $13.5 million in the third quarter of 2026, up 18% from $11.4 million in the second quarter; revenue was not recognized for one treatment whose batch failed the identity assay release criterion. Abeona Q3 2026 results release (8-K, Item 2.02) · as of
- Company news reported third-quarter sales of $13.491 million against an analyst estimate of $16.484 million, and loss per share of $0.08 against an estimate of $0.15. Company news, 9 November 2026 · as of
- Fifteen ZEVASKYN treatments have been completed since launch, six in the third quarter; the eight-center network has four centers with completed treatments. Abeona Q3 2026 results release · as of
- Cash, cash equivalents and short-term investments were $134.9 million at 30 September 2026, down from $146.8 million at 30 June 2026, excluding $30 million of gross private placement proceeds received after quarter end. Abeona Q3 2026 results release · as of
- Abeona acquired ABO-801 from Ellodi Pharmaceuticals for $20 million of common stock at closing, with $30 million due on FDA approval, up to $30 million in sales milestones and low-to-mid-teen percentage royalties. Abeona 8-K (acquisition and unregistered sales of equity securities) · as of
- The private placement raised $30 million at $3.75 per share, with Morgan Stanley as placement agent. Panabee summary of Abeona release · as of
- HC Wainwright maintained a Buy rating and lowered its price target to $18. Company news, HC Wainwright & Co. · as of
- Four executives sold shares at $5.16 on 29 September 2026 (19,608; 9,191; 6,727; 4,902 shares), and a director sold 15,000 shares at $5.86 on 1 September 2026. SEC Form 4 filings · as of
Sources
- ABEONA THERAPEUTICS INC. - Form 8-K - FY2026 · sec.gov ·
- Abeona Acquires Phase 3-Ready ABO-801 for $20 Million Stock and Secures $30 Million Private Placement · panabee.com
- Abeona Q3 ZEVASKYN Revenue Grows 18% to $13.5 Million Supported by NTAP Status and $135 Million in Cash · panabee.com
- BioPharmaWatch
Related · shared themes
TVTX
Travere Therapeutics
Travere Therapeutics' FILSPARI kidney-drug sales beat the third-quarter benchmark at $200.2 million, but new patient start forms slipped to…
ARCT
Arcturus Therapeutics Holdings
Arcturus Therapeutics has cash into 2028 but no dated FDA path for ARCT-810 and no dated Phase 3 decision for ARCT-032, so the shares are…
DSGN
Design Therapeutics
Design Therapeutics' shares are more likely to lag the S&P 500: a new $200 million stock-sale program adds supply while DT-216P2's…
MGTX
MeiraGTx Holdings
MeiraGTx's shares are more likely to lag the S&P 500 over three months: the US filing for its gene therapy bota-vec slipped to the first…
See also · stocks to watch